

Familial Breast Cancer Advisory Committee Interests Register

Register last updated: 08/04/26

All interests have been signed off by the Chair and the NICE Developer Lead

| Name | Role on the committee | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|----------------|--------------------------|---|--|----------------|-------------------|-----------------|---|
| Alison Cameron | Committee member - Chair | Direct-financial | Consultant Clinical Oncologist, University Bristol and Weston NHS Foundation Trust. | 06/07 | 03/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Alison Cameron | Committee member - Chair | Direct, non-financial professional and personal | I am a member of the Royal College of Radiologists Society Training Board and curriculum committee. This role is unpaid. This is not directly related to the guideline, but we may have teaching sessions related to this content. | 2021 | 03/25 | Ongoing | Non-specific Declare and participate |
| Alison Cameron | Committee member - Chair | Direct, non-financial professional and personal | I am a Royal College of Radiologists e-learning lead for Clinical Oncology. This role is unpaid. This is not directly related to the guideline, but we may have teaching sessions related to this content. | 12/24 | 03/25 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|-------------------------|--|---|--|-------|-------|---------|---|
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct-financial | Breast Advanced Nurse Practitioner, Royal Liverpool Hospital. | 08/14 | 05/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Nurse member on the education and training committee for the Association of Breast Surgery. This role is unpaid. | 05/25 | 05/25 | Ongoing | Non-specific Declare and participate |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Davies-Crowley K, Brooks R. Expanding role of the breast advanced nurse practitioner: mainstream pathway for genetic testing . Br J Nurs. 2025 May 22;34(10):S26-S30. doi: 10.12968/bjon.2024.0474. PMID: 40396950. | 05/25 | 05/25 | 05/25 | Non-specific Declare and participate |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Potter S, Fairhurst K, Cowan K, Vincent S, Lewis I, Cutress RI, Stobart H, Fairbrother P, Turner S, Davies-Crowley K, Jeevan R, Rattay T, O'Connell R, Bundred N, McIntosh SA. Identifying research priorities in breast cancer surgery: a UK priority setting | 11/22 | 05/25 | 11/22 | Non-specific Declare and participate |

| | | | | | | | |
|-------------------------|--|---|--|-------|-------|-------|---|
| | | | partnership with the James Lind Alliance . Breast Cancer Res Treat. 2023 Jan;197(1):39-49. doi: 10.1007/s10549-022-06756-4. Epub 2022 Nov 1. PMID: 36319906; PMCID: PMC9628302. | | | | |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Service evaluation of newly established breast mainstream genetic R208 panel testing undertaken at liverpool university hospital foundation trust (LUHFT) Davies-Crowley, Kayleigh, Brooks, Rebecca European Journal of Surgical Oncology, Volume 51, 109818 DOI: 10.1016/j.ejso.2025.109818 | 05/25 | 05/25 | 05/25 | Non-specific Declare and participate |
| Kayleigh Davies-Crowley | Committee member – Advanced Nurse Practitioner | Direct, non-financial professional and personal | Outcomes of advice and guidance referrals to a large breast surgery service Lennon, Hannah et al. | 05/24 | 05/25 | 05/24 | Non-specific Declare and participate |

| | | | | | | | |
|-----------------|--|---|---|-------|-------|---------|---|
| | | | <p>May 2024 European Journal of Surgical Oncology 50:108134</p> <p>DOI: 10.1016/j.ejso.2024.108134</p> | | | | |
| Rachael Griffin | Co-opted member – Lay member | Direct-financial | <p>I work for a company (Jazz Pharmaceuticals) that runs clinical trials. Some in breast cancer as they are trials for the drug Zanidatamab. However, I am not involved in the trials themselves. I work in Clinical Outsourcing - overseeing our 3rd party suppliers.</p> | 04/22 | 07/25 | Ongoing | Non-specific Declare and participate |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | <p>UK Cancer Genetics Group (UKCGG): Chair of UKCGG (Term 2021-2024) - retiring Chair May 2024-2025.</p> <p>Led on improving access and consistency of care of patients with rare inherited predisposition syndrome.</p> <p>I received no payment or honorarium for this role</p> | 01/23 | 03/25 | 05/25 | Non-specific Declare and participate |

| | | | | | | | |
|--------------|--|--|---|-------|-------|-------|--|
| | | | other than travel expenses. | | | | |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal and indirect-financial | <p>Co-investigator on "CanGene-CanVar" a 5-year £4.3 million Cancer Research UK catalyst award-funded programme. (Sept 2019 –March 2025) as part of Work Package 3 :Translation and implementation of Clinical Guidelines.</p> <p>Research monies went to my institution.</p> <p>During this time I have co-authored and published a number of papers on recommended clinical management of individuals with inherited cancer predisposition, including those with a predisposition to breast cancer. Those relevant to breast cancer are included below.</p> | 09/19 | 03/25 | 03/25 | Specific Declare and participate Individual papers assessed below. |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | <p>Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the</p> | 01/25 | 03/25 | 01/25 | Specific Declare and participate |

| | | | | | | | |
|--------------|--|---|--|-------|-------|-------|---|
| | | | <p>American College of Medical Genetics and Genomics (ACMG). Pal T, Schon KR, Astiazaran-Symonds E, Balmaña J, Foulkes WD, James P, Klugman S, Livinski AA, Mak JS, Ngeow J, Voian N, Wick MJ, Hanson H, Stewart DR, Tischkowitz M; ACMG Professional Practice and Guidelines Committee. Genet Med. 2025 Jan;27(1):101243. doi: 10.1016/j.gim.2024.101243. PMID: 39636577</p> | | | | Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | <p>Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing. Rowlands CF, Allen S, Balmaña J, Domchek SM, Evans DG, Hanson H, Hoogerbrugge N, James PA, Nathanson KL, Robson M, Tischkowitz M, Foulkes WD, Turnbull C. Ann Oncol. 2024 Oct;35(10):892-901. doi: 10.1016/j.annonc.2024.07.244. PMID: 38986768.</p> | 10/24 | 03/25 | 10/24 | Non-specific Declare and participate |

| | | | | | | | |
|--------------|---|---|---|-------|-------|-------|--|
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Digital innovation for cancer risk assessment allows large-scale service redevelopment of regional cancer genetics service delivery. Youngs A, Forman A, Elms M, Kohut K, Hlaing MT, Short J, Hanson H, Snape K. Fam Cancer. 2024 Nov;23(4):591-598. doi: 10.1007/s10689-024-00407-x. PMID: 38954285; | 11/24 | 03/25 | 11/24 | Non-specific Declare and participate |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice. Tsoulaki O, Tischkowitz M, Antoniou AC, Musgrave H, Rea G, Gandhi A, Cox K, Irvine T, Holcombe S, Eccles D, Turnbull C, Cutress R; Meeting Attendees; Archer S, Hanson H.. Br J Cancer. 2024 Jun;130(12):2027-2036. doi: 10.1038/s41416-024-02733-4. PMID: 38834743 | 06/24 | 03/25 | 06/24 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|---|---|---|-------|-------|-------|--|
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling study. Huntley C, Torr B, Kavanaugh G, George A, Hanson H, Snape K, Broggio J, Glasgow L, Tischkowitz M, Evans DG, Antoniou AC, Turnbull C. Br J Gen Pract. 2024 Aug 29;74(746):e610-e618. doi: 10.3399/BJGP.2023.0327. PMID: 38724186 | 08/24 | 03/25 | 08/24 | Non-specific Declare and participate |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer McDevitt T, Durkie M, Arnold N, Burghel GJ, Butler S, Claes KBM, Logan P, Robinson R, Sheils K, Wolstenholme N, Hanson H, Turnbull C, Hume S. Eur J Hum Genet. 2024 Mar 5. doi: | 03/24 | 03/25 | 03/24 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|--|---|---|-------|-------|-------|--|
| | | | 10.1038/s41431-023-01507 PMID: 38443545 | | | | |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risks Giblin J, Coad B, Lamb C, Berlin C, Rea G, Hanson H, Snape K, Berner A; Consensus Meeting attendees. BJC Rep. 2023 Jun 22;1(1):1. doi: 10.1038/s44276-023-00002-0. PMID: 39516684; | 06/22 | 03/25 | 06/22 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Hanson H, Astiazaran Symonds, M. Amendola L, Balmaña J, Foulkes W, James P, Klugman S, Ngeow J, Schmutzler R, Voian N, Wick M, Pal T, Tischkowitz M, Stewart D; on behalf of | 10/23 | 03/25 | 10/23 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|--|---|--|-------|-------|-------|--|
| | | | the ACMG Professional Practices and Guidelines Committee. Genet Med. 2023 Oct;25(10):100870. doi: 10.1016/j.gim.2023.100870. PMID: 37490054 | | | | |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F. J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. PMID: 36411 | 11/22 | 03/25 | 11/22 | Specific Declare and participate Despite being specific to the topic under consideration this paper would not be included in the evidence base for the review questions in the update. |

| | | | | | | | |
|--------------|---|---|---|-------|-------|---------|--|
| Helen Hanson | Committee member - Clinical Geneticist | Direct-financial | Consultant in Cancer Genetics, Royal Devon University Healthcare NHS Foundation Trust | 09/23 | 03/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Helen Hanson | Committee member - Clinical Geneticist | Direct-financial | Associate Professor Clinical Cancer Genetics, University of Exeter Medical School | 09/23 | 03/25 | Ongoing | Declare and participate Salaried employment |
| Helen Hanson | Committee member - Clinical Geneticist | Direct, non- financial professional and personal | Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. J Med Genet. 2025 Oct 1;jmg- 2025-110979. doi: 10.1136/jmg-2025- 110979. Epub ahead of print. PMID: 41159931. | 10/25 | 01/26 | | Non-specific Declare and participate |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Salaried General Practitioner, Rosebank Health Primary Care Network, Gloucester | 2017 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |

| | | | | | | | |
|-------------|---|------------------|--|-------|-------|---------|--|
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Clinical Lead Cancer, NHS Gloucestershire | 2013 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Breast Physician, Gloucestershire Hospitals NHS Foundation Trust | 2022 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Chair Gloucestershire GP Education Trust - this is a membership charitable organisation offering aspirational GP education with local provider colleagues and as Education Programme Director and Honorary Tutor I take an active role in forming policy/ strategy and planning/ facilitating educational events. I kite- mark all GGPET education sessions for quality of GP education. I attend NHS Gloucestershire's monthly HEE Training Hub meetings. | 2013 | 06/25 | Ongoing | Declare and participate Salaried employment in non-profitable organisation |
| Sadaf Haque | Committee member – General Practitioner | Direct-financial | Gloucestershire LMC Medical Executive I am an appointed salaried officer of the LMC serving | 11/25 | 12/25 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|--------------|--|---|---|-------|-------|---------|--|
| | | | in a non-voting capacity and cannot hold elected officer position on the Gloucestershire Committee. I provide professional support to the Gloucestershire local Committee, dedicate time to LMC matters, and keep the Committee informed of local, regional, and national issues. | | | | |
| Ashley Hurst | Committee member – Lay member | Direct, non-financial professional and personal | Member of NICRCF (Northern Ireland Cancer Research Consumer Forum) | | 06/25 | | Non-specific Declare and participate |
| Ashley Hurst | Committee member – Lay member | Direct, non-financial professional and personal | PPI Member of NiCAN Breast CRG (Northern Ireland Cancer Network Breast Clinical Reference Group). | | 06/25 | | Non-specific Declare and participate |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct-financial | Consultant in Cancer Genetics and Breast Medical Oncology, Royal Marsden Hospital | 12/12 | 03/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct-financial | Private practice at Royal Marsden, 2 hours per week (approximately 6% of my overall practice is private). This includes | 04/21 | 03/25 | Ongoing | Declare and participate Private practice represents 6% of overall practice. |

| | | | | | | | |
|----------|--|---|--|-------|-------|-------|--|
| | | | germline genetic testing primarily for breast cancer patients. | | | | |
| Zoe Kemp | Committee member - Clinical Geneticist | Indirect-financial | I work one day a week on an NHS Transformation programme for genetic testing in breast cancer patients. This research day is with the Institute for Cancer Research and is funded by an SBRI Healthcare grant. Research funding goes to the institute. | 2024 | 03/25 | 03/25 | Specific Declare and participate Open declaration is sufficient mitigation |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct-financial | I gave an educational talk for Pfizer and received honorarium. The presentation was on germline testing for breast cancer patients and which patients were eligible under the National Test Directory. | 2024 | 03/25 | 2024 | Specific Declare and participate Reimbursement is reasonable in return of expertise. |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Attendance at the San Antonio Breast Cancer Symposium 9-12 December 2025. I am not presenting however I am an author on an accepted poster. All expenses to | 12/25 | 11/25 | 12/25 | Non-specific Declare and participate |

| | | | | | | | |
|----------|--|---|---|-------|-------|---------|---|
| | | | attend have been covered personally. | | | | |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. J Med Genet. 2025 Oct 1;jmg-2025-110979. doi: 10.1136/jmg-2025-110979. Epub ahead of print. PMID: 41159931. | 10/25 | 01/26 | | Non-specific Declare and participate |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Participation in the BRCA BCY Collaboration (international, hospital-based, retrospective cohort study). Publications from collaboration: Association between risk-reducing surgeries and survival in young BRCA carriers with breast | 02/24 | 02/26 | Ongoing | Specific Declare and partial exclusion Included study for RQ5 on risk-reducing mastectomy Participate in discussion but withdraw from recommendation drafting. |

| | | | | | | | |
|-------------|--|---|---|-------|-------|---------|---|
| | | | cancer: an international cohort study Lancet Oncology 2025 Jun;26(6):759-770 | | | | |
| Zoe Kemp | Committee member - Clinical Geneticist | Direct, non-financial professional and personal | Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study Ann Oncol. 2026 Mar;37(3):364-377 | 02/24 | 02/26 | 02/24 | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct financial | Consultant Breast Radiologist, Queen Elizabeth Hospital | 02/17 | 10/22 | Ongoing | Declare and participate Salaried employment in the NHS |
| Simon Lowes | Coopted member - Radiologist | Direct financial | Research collaboration with IbeX Innovations to develop novel mammography techniques. For this I receive the equivalent of 2 hours per week remuneration. | 11/19 | 10/22 | 10/25 | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct financial | Joint Radiology Lead for the National Breast Imaging Academy's | 12/18 | 10/22 | 03/26 | Non-specific Declare and participate |

| | | | | | | | |
|-------------|------------------------------|--|---|-------|-------|---------|---|
| | | | “Academy Online” e-Learning Programme. For this I receive the equivalent of 2 hours per week remuneration. | | | | |
| Simon Lowes | Coopted member - Radiologist | Direct financial | NIHR Imaging Group member, and chair of the Workforce Working Group; NIHR North East North Cumbria Research Delivery Network Specialty Lead for Imaging. For this SL receives the equivalent of 2 hours per week in job-planned time. | 10/22 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Treasurer/Executive Committee Member, British Society of Breast Radiology | 11/19 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Advisory Editor/Editorial Board member, Clinical Radiology | 08/19 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Radiology Lead for iBRANET Localisation group, a national group assessing non-guidewire devices for localising breast cancers prior to surgery | 06/21 | 10/22 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|-------------|------------------------------|--|--|-------|-------|---------|---|
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Member of the Sloane Project Steering Group, investigating screen-detected in situ breast malignancies and atypias | 10/21 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Local PI for the SMALL trial, investigating vacuum-assisted excision of grade 1 screen-detected breast cancers | 10/21 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Local PI for the PICASSO study, a pilot study investigating vacuum-assisted excision of breast cancers in women unsuitable for surgery | 11/18 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Indirect | Committee Member, Women's Cancer Detection Society, a Gateshead-based charity supporting research and treatment of breast cancer | 02/21 | 10/22 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Royal College of Radiologists Academic Committee Member | 01/25 | 02/25 | Ongoing | Non-specific Declare and participate |

| | | | | | | | |
|-------------|------------------------------|--|---|-------|-------|---------|---|
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | NIHR Imaging Group member, and chair of the Workforce Working Group | 04/23 | 02/25 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Member of the Royal College of Radiologists Professional Practice Board | 08/25 | 09/25 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Associate Editor (Breast) British Journal of Radiology | 01/25 | 04/26 | Ongoing | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct-financial | Speaker fees from Hologic, Merit Medical, and Sirius Medical, These sessions were on pre-operative breast lesion localisation to healthcare professionals and were not directly linked to familial breast cancer. | 09/25 | 04/26 | 09/26 | Non-specific Declare and participate |
| Simon Lowes | Coopted member - Radiologist | Direct-financial | Honorarium for medical advisory board group membership Merit Medical. This was for product development advice – not related to familial breast cancer. | 01/26 | 04/26 | 01/26 | Non-specific Declare and participate |

| | | | | | | | |
|-------------|---------------------------------------|--|---|-------|-------|---------|---|
| Simon Lowes | Coopted member - Radiologist | Direct, non-financial, professional and personal | Chair of the NIHR Imaging Group Workforce Working Group | 03/24 | 03/24 | 10/24 | Non-specific Declare and participate |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct-financial | Consultant Genetic Counsellor, Manchester Centre for Genomic Medicine | 08/21 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Woodward ER, Lalloo F, Forde C, Pugh S, Burghel GJ, Schlecht H, Harkness EF, Howell A, Howell SJ, Gandhi A, Evans DG. Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400. J Med Genet. 2024 Mar 21;61(4):385-391. doi: 10.1136/jmg-2023-109671 . PMID: 38123987. | 03/24 | 07/25 | | Non-specific Declare and participate |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Evans DG, Burghel GJ, Howell SJ, Pugh S, Forde C, Howell A, Lalloo F, Woodward ER. | 08/24 | 07/25 | | Non-specific Declare and participate |

| | | | | | | | |
|------------|---------------------------------------|---|---|-------|-------|--|--|
| | | | Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2. J Med Genet. 2024 Aug 29;61(9):853-855. doi: 0.1136/jmg2023-109826 . PMID: 38609177; PMCID: PMC11420751 | | | | |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Sodde P, Hyder Z, Pugh S, Lalloo F, Martin R, Soh C, Naqvi J, Whitehouse R, Evans DG, Woodward ER. Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome. J Med Genet. 2025 Jun 30;jmg-2025-110704. doi: 10.1136/jmg-2025-110704 . Epub ahead of print. PMID: 40588398. | 06/25 | 07/25 | | Specific Declare and participate Keep under review based on the topic under consideration. |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Evans DG, Morgan RD, Forde C, Crosbie EJ, Burghele GJ, Pugh S, Gandhi A, Howell A, Howell SJ, Woodward ER, Lalloo F. Validation of the pathology-adjusted Manchester scoring | 11/25 | 12/25 | | Specific Declare and participate Keep under review while included studies are identified for RQ1 on diagnostic risk tools. |

| | | | | | | | |
|---------------|---------------------------------------|---|--|-------|-------|---------|---|
| | | | system in over 10 000 assessments of cases with breast and/or ovarian cancer. J Med Genet. 2025 Nov 19;jmg-2025-110869. doi: 10.1136/jmg-2025-110869 . Epub ahead of print. PMID: 41260924. | | | | |
| Sarah Pugh | Committee member – Genetic Counsellor | Direct, non-financial professional and personal | Member of consensus group / not co-author: Christopher J, Edgerley K, McIldowie B, Jewell R, Kemp Z, Snape K, Hanson H; Consensus meeting attendees. Recontact and follow-up for individuals with germline pathogenic variants in hereditary breast and ovarian cancer susceptibility genes: a UK Cancer Genetics Group consensus meeting. J Med Genet. 2025 Oct 1;jmg-2025-110979. doi: 10.1136/jmg-2025-110979 . Epub ahead of print. PMID: 41159931. | 10/25 | 12/25 | | Non-specific Declare and participate |
| Kathryn Rigby | Committee member – Breast Surgeon | Direct-financial | Consultant Oncoplastic Breast Surgeon – Doncaster & Bassetlaw | 2012 | 06/25 | Ongoing | Declare and participate Salaried employment in the NHS |

| | | | | | | | |
|-----------------|--|---|--|-------|-------|---------|---|
| | | | Teaching Hospitals NHS Trust | | | | |
| Kathryn Rigby | Committee member – Breast Surgeon | Non-financial professional and personal | Member of Association of Breast Surgery Clinical Standards and Practice committee, as a regional representative and then communications representative. We review and publish guidance/ information on relevant topics for ABS members, clinical and non-clinical. | 2017 | 06/25 | Ongoing | Non-specific Declare and participate |
| Tamsin Sargeant | Committee member – Lay member | Direct, non-financial professional and personal | I'm a volunteer for Breast Cancer Now and I offer telephone and email support to women around their breast cancer diagnosis, including familial breast cancer. | 2013 | 05/25 | Ongoing | Non-specific Declare and participate |
| Hannah Seabrook | Committee member – Clinical Psychologist | Direct-financial | I currently work as a Consultant Clinical Psychologist within the NHS in an Oncology Service that offers risk reducing mastectomy assessments for University Hospitals Coventry and Warwickshire NHS Trust. | 06/18 | 05/25 | Ongoing | Declare and participate Salaried employment in the NHS |

| | | | | | | | |
|-----------------|--|---|--|-------|-------|---------|---|
| Hannah Seabrook | Committee member – Clinical Psychologist | Direct, non- financial professional and personal | I am part of a group of psychologists updating the professional guidance for the psychological assessment of women considering risk reducing breast surgery. This is still in the very early stages. | 02/26 | 03/26 | Ongoing | Non-specific Declare and participate Whilst related to RQ5 our review is focusing on who could benefit from risk- reducing mastectomy. |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Consultant Clinical Oncologist, Ipswich Hospital | 03/03 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Clinical Director for Oncology and Haematology across East Sussex and North Essex NHS Foundation Trust. Includes Chair of rapid decision group for chemotherapy prescribing in Trust wide electronic patient record and member of multidisciplinary cross-site genomics meeting establishing genetic and genomic testing pathways. | 09/21 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Clinical Lead, Oncology | 03/19 | 07/25 | Ongoing | Declare and participate Salaried employment in the NHS |

| | | | | | | | |
|-------------|---|------------------|---|-------|-------|--|--|
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to attend ESMO Breast 2024 | 05/24 | 07/25 | | Specific Declare and participate Attendance at conference. |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis to discuss breast cancer treatment (use of Ribociclib for advanced breast cancer). Not relevant to topic under consideration. | 12/24 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis discussing breast cancer treatment (use of Ribociclib for advanced breast cancer). Not relevant to topic under consideration. | 10/23 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis (use of Ribociclib for advanced breast cancer). Relevant to breast cancer but not topic under consideration. | 08/23 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to chair meeting for Novartis. Relevant to breast cancer but not topic under consideration. | 02/23 | 07/25 | | Non-specific Declare and participate |

| | | | | | | | |
|-------------|--|------------------|--|-------|-------|---------|--|
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Payment to attend meeting to discuss breast cancer by Daachi Sanyo. This relates to use of Enhertu for metastatic Her 2 positive breast cancer. | 04/25 | 07/25 | | Non-specific Declare and participate |
| Liz Sherwin | Committee member – Clinical Oncologist | Direct-financial | Paid host of Novartis sponsored evening educational meeting discussing role of adjuvant ribociclib. Relevant to breast cancer but not topic under consideration. | 09/25 | 11/25 | 09/25 | Non-specific Declare and participate |
| William Teh | Coopted member – Radiologist | Direct financial | Consultant breast radiologist, Northwick Park & North London Breast Screening | 1998 | 01/26 | Ongoing | Declare and participate. Salaried employment in NHS |
| William Teh | Coopted member – Radiologist | Direct financial | Director of London Breast Screening Hub, Royal Free Hospital. | 2016 | 01/26 | Ongoing | Declare and participate. Salaried employment in NHS |
| William Teh | Coopted member – Radiologist | Direct financial | Private practice at HCA, Circle, Spire, London Clinic. Approx. 10% of practice is private and private practice mirrors NHS practice. | | 01/26 | Ongoing | Specific. Declare and participate. Private practice is limited |

| | | | | | | | |
|-------------|------------------------------|---|--|--|-------|---------|--|
| William Teh | Coopted member – Radiologist | Direct financial | Radiology advisor HCA | | 01/26 | | Specific. Declare and participate. Private practice is limited |
| William Teh | Coopted member – Radiologist | Direct, non-financial professional and personal | PI for NIHR research: PROSPECTS (To compare the cost-effectiveness of breast cancer screening using digital breast tomosynthesis or standard mammograms) | | 01/26 | Ongoing | Non-specific Declare and participate |
| William Teh | Coopted member – Radiologist | Direct, non-financial professional and personal | PI for NIHR research: BRAID (Breast screening—Risk Adapted Imaging for Density) study | | 01/26 | Ongoing | Non-specific Declare and participate |
| William Teh | Coopted member – Radiologist | Direct, non-financial professional and personal | PI for NIHR research: SMALL (looking at overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision). | | 01/26 | Ongoing | Non-specific Declare and participate |
| William Teh | Coopted member – Radiologist | Direct, non-financial | PI for NIHR research: CESAR | | 01/26 | Ongoing | Non-specific |

| | | | | | | | |
|-------------|------------------------------|---|--|-------|-------|---------|---|
| | | professional and personal | (Contrast Enhanced mammography versus magnetic reSonace imaging for Assessing Response to neoadjuvant chemotherapy). | | | | Declare and participate |
| William Teh | Coopted member – Radiologist | Direct, non-financial professional and personal | PI for NIHR research: EDITH (Early Detection using Information Technology in Health) | | 01/26 | Ongoing | Non-specific Declare and participate |
| William Teh | Coopted member – Radiologist | Direct, non-financial professional and personal | Radiology Professional Clinical Advisor for NHSE SQAS (screening QA) | 2009 | 01/26 | Ongoing | Non-specific Declare and participate |
| William Teh | Coopted member – Radiologist | Direct | NHS BSP clinical adviser | 07/05 | 04/25 | Ongoing | Non-specific Declare and participate |

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice. Dates to be given MM/YY unless the actual date is key to the declaration.